Pharmaceutical Articles

Beasley Allen has one of the largest and most technologically advanced Mass Torts practices in the country. The Mass Torts division represents numerous people in claims against companies that manufacture and/or market defective pharmaceuticals and/or medical devices. The resources devoted to this division allow the firm to competently and conscientiously handle any group of cases, no matter how large, along with particular catastrophic injury cases.

Our firm was recently involved in one of the greatest victories in Mass Torts history, against drug manufacturer Merck regarding the drug Vioxx. After more than five years of hard-fought and difficult litigation, Merck agreed to pay $4.85 billion, the largest pharmaceutical settlement in U.S. history, to resolve certain Vioxx-related claims involving plaintiffs who suffered a heart attack, including sudden cardiac death, or a stroke.

Testosterone therapy does not appear to work in obese men with type 2 diabetes

Posted: August 1, 2014

Testosterone replacement therapy is designed to treat symptoms of “Low T,” such as low libido, weight gain, and fatigue; however, the treatment doesn’t appear to work on aging, obese men with type 2 diabetes, a new study shows.

Hospira recalls injectable anesthetic Lidocaine due to particles floating in solution

Posted: August 1, 2014

Hospira, Inc., is recalling one lot of its injectable drug Lidocaine because of a confirmed report of discolored solution with visible particles floating in it as well as particulate embedded in the molded glass container. Hospira has identified the particulate

Hospital CO2 detector accessories recalled due to life threatening defect

Posted: August 1, 2014

GE Healthcare is recalling accessories for its CO2 detectors because they may cause the device to fail or to provide incorrect CO2 values for mechanically and spontaneous ventilated patients. Physicians rely on these devices to make decisions, and if those

Mental health groups ask FDA to remove black box warning for suicide risk from antidepressants

Posted: August 1, 2014

Mental health experts are petitioning the Food and Drug Administration (FDA) to remove its severest warning involving suicidal thoughts from the safety labels on all antidepressants because the warning has resulted in a 33 percent increase in suicide attempts, and has

Canadian regulators warn consumers about cardiovascular risks of testosterone drugs

Posted: July 31, 2014

Canada’s national health regulators have issued a warning to consumers and health care providers about the serious risks associated with the use of testosterone-replacement drugs, which are being prescribed to increasing numbers of men as a treatment for low natural

Did Boehringer Ingelheim withhold safety information about blood thinner Pradaxa?

Posted: July 31, 2014

When Pradaxa (dabigatran) hit the market in 2010 to prevent strokes in patients with atrial fibrillation, it became the first alternative treatment to the long-used warfarin for patients with the condition. What made Pradaxa so attractive compared to warfarin (Coumadin)

Experts worry about skyrocketing prescriptions for antidepressants

Posted: July 31, 2014

The number of prescriptions for antidepressants has reached a record high in the United Kingdom, and experts fear that some people may be unnecessarily exposed to antidepressant side effects.

Fresenius faces more than 5,500 NaturaLyte, GranuFlo lawsuits

Posted: July 30, 2014

Fresenius Medical Care, the world’s largest provider of dialysis services and products, is facing more than 5,500 lawsuits alleging the company’s dialysis concentrates caused patients to suffer sudden cardiac arrest.

New meta-analysis raises serious questions about SSRI use during pregnancy

Posted: July 30, 2014

There is not enough research to provide a clear guidance on the risks or benefits of antidepressant use during pregnancy, however there are serious concerns regarding the drugs’ affects on newborns that should be addressed, a new meta-analysis has found.

European advisors recommend approval of new combination type 2 diabetes treatment

Posted: July 29, 2014

An advisory panel for European drug regulators is recommending approval for a new type 2 diabetes drug combining the long-acting insulin degludec with Victoza (liraglutide). The favorable recommendation of Novo Nordisk’s drug Xultophy, previously known as IDegLira, was based on